Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline Mesylate Extension Study in Parkinson's Disease
NCT00203138Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2004
- Primary completion
- Nov 2006
- Modality
- Irreversible Covalent Inhibitors
01
Overview
A Phase 3 trial of rasagiline in Parkinson's disease (PD), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jun 2004; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00203138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203138.